Our results indicate that L861Q is an active mutation to EGFR-TKIs in ESCC cell lines; however, the 1% frequency of EGFR mutation in ESCC makes it difficult to stratify patients who may benefit from EGFR-TKI treatment, compared with NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.